Key result
MTCA-KKV was superior to MTCA in accumulating on activated platelets and inhibiting platelet aggregation, with an IC50 approximately 1/10 that of MTCA.
Why the study?
Does MTCA-KKV improve targeting and inhibition of activated platelets compared to MTCA in preclinical models?
Does MTCA-KKV improve targeting and inhibition of activated platelets compared to MTCA in preclinical models?
Modification of the platelet inhibitor MTCA with the KKV peptide significantly enhances its accumulation on activated platelets and its inhibitory potency in vitro.
Answers are grounded in this paper and cite their sources.
MTCA-KKV may enhance targeted platelet inhibition in preclinical models; leaves open translation to clinical antiplatelet strategies.
Aim: The modification of platelet inhibitor to enhance its targeting capacity toward platelets is of clinical importance. Thus, (1R, 3S)-1-methyl-1, 2, 3, 4-tetrahydro-β-carboline-3-carboxylic acid (MTCA), a platelet inhibitor, was modified with Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val (KKV), platelet targeting peptide, to form MTCA-KKV. Materials & methods: MTCA and MTCA-KKV were synthesized to identify the effect of KKV modification on MTCA and platelets. Results: Atomic force microscopy imaged MTCA-KKV effectively accumulated on activated platelets. UV spectra showed that MTCA-KKV concentration dependently changed P-selectin and GPIIb/IIIa conformations. For platelet aggregation, the IC50 of MTCA-KKV was approximately 1/10 folds of MTCA. Conclusion: KKV modification led to forming MTCA-KKV that is superior to MTCA in terms of accumulating on activated platelets, targeting P-selectin and GPIIb/IIIa and inhibiting platelet aggregation. MTCA-KKV could be a promising lead for further investigation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied Platelet aggregation. MTCA-KKV vs. MTCA was evaluated on Platelet aggregation (IC50) (IC50 approximately 1/10 folds of MTCA). MTCA-KKV was superior to MTCA in accumulating on activated platelets and inhibiting platelet aggregation, with an IC50 approximately 1/10 that of MTCA.
Synapse has enriched 10 related papers. Consider them for comparative context: